Proven Technology and Business Viability with Real-Time Multi-Biosignal Monitoring Technology

[Medical Newspaper · Daily Bosa = Reporter In-gyu Oh]

Mezoo, led by CEO Jung-hwan Park, recently passed the technology evaluation required for a technology special listing on KOSDAQ after receiving grades of A and BBB from specialized evaluation agencies designated by the Korea Exchange.

The technology evaluation is the first major gateway for a technology special listing on KOSDAQ and assesses a company’s core technologies and market potential. To pass, a company must obtain at least an A grade and a BBB grade from two evaluation institutions officially designated by the Korea Exchange.

As a leading company in Korea’s wearable ambulatory remote patient monitoring market, Mezoo is driving innovation in clinical settings with its proprietary real-time multi-biosignal wireless transmission technology.

The HiCardi series has secured a 53 percent share of the nation’s tertiary hospitals, having been adopted by 25 out of 47 institutions, and is currently in use at more than 600 medical institutions nationwide, demonstrating both strong technological competitiveness and proven market dominance.